NO20000366L - O-substituerte hydroksycoumaranon-derivater som anti-tumor- og antimetastase-midler - Google Patents
O-substituerte hydroksycoumaranon-derivater som anti-tumor- og antimetastase-midlerInfo
- Publication number
- NO20000366L NO20000366L NO20000366A NO20000366A NO20000366L NO 20000366 L NO20000366 L NO 20000366L NO 20000366 A NO20000366 A NO 20000366A NO 20000366 A NO20000366 A NO 20000366A NO 20000366 L NO20000366 L NO 20000366L
- Authority
- NO
- Norway
- Prior art keywords
- agents
- hydroxycoumaranone
- antimetastasis
- tumor
- derivatives
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 239000002257 antimetastatic agent Substances 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- VQTUMNNCKYTZSR-UHFFFAOYSA-N 3-hydroxy-3h-1-benzofuran-2-one Chemical class C1=CC=C2C(O)C(=O)OC2=C1 VQTUMNNCKYTZSR-UHFFFAOYSA-N 0.000 title 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000005504 styryl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97113190 | 1997-07-31 | ||
| EP98106946 | 1998-04-16 | ||
| PCT/EP1998/004619 WO1999006387A2 (en) | 1997-07-31 | 1998-07-23 | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20000366L true NO20000366L (no) | 2000-01-25 |
| NO20000366D0 NO20000366D0 (no) | 2000-01-25 |
Family
ID=26145681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000366A NO20000366D0 (no) | 1997-07-31 | 2000-01-25 | O-substituerte hydroksycoumaranon-derivater som anti-tumor- og antimetastase-midler |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6200989B1 (de) |
| EP (1) | EP1012147B1 (de) |
| JP (1) | JP3241711B2 (de) |
| KR (1) | KR100343067B1 (de) |
| AR (1) | AR013374A1 (de) |
| AT (1) | ATE308535T1 (de) |
| AU (1) | AU745839B2 (de) |
| BR (1) | BR9811589A (de) |
| CA (1) | CA2296476A1 (de) |
| DE (1) | DE69832184D1 (de) |
| HR (1) | HRP20000031A2 (de) |
| HU (1) | HUP0004221A2 (de) |
| ID (1) | ID24525A (de) |
| IL (1) | IL134193A0 (de) |
| MA (1) | MA26528A1 (de) |
| NO (1) | NO20000366D0 (de) |
| PE (1) | PE106099A1 (de) |
| PL (1) | PL338614A1 (de) |
| TR (1) | TR200000272T2 (de) |
| UY (1) | UY25114A1 (de) |
| WO (1) | WO1999006387A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU736869B2 (en) * | 1999-01-30 | 2001-08-02 | Roche Diagnostics Gmbh | O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents |
| AU2002362030A1 (en) * | 2001-11-27 | 2003-06-10 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| AU2002358158A1 (en) * | 2001-12-19 | 2003-06-30 | D. Collen Research Foundation | Use of urokinase receptor antagonists to modulate ischemiareperfusion injury |
| WO2004076444A2 (en) * | 2003-02-25 | 2004-09-10 | F. Hoffmann-La Roche Ag | Novel hydroxycoumaranone derivatives as antitumor and antimetastatic |
| EP2077260B1 (de) * | 2006-10-27 | 2015-02-18 | The University of Tokyo | Amidverbindung oder salz davon und inhibitor der bildung von biologischen filmen, substanz zum entfernen biologischer filme und bakterizid, bei denen jeweils die amidverbindung oder ein salz davon verwendet wird |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| PT109740B (pt) * | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
| AU2018289303B2 (en) | 2017-06-20 | 2023-12-21 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| PT3697785T (pt) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Compostos de imidazopiridina como inibidores de pad |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| AU2018383675A1 (en) | 2017-12-13 | 2020-07-09 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
| SG11202011014VA (en) * | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| JP6611029B1 (ja) * | 2018-11-05 | 2019-11-27 | プキョン ナショナル ユニバーシティ インダストリ ユニバーシティ コーポレーション ファウンデーションＰｕｋｙｏｎｇ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 高周波超音波多焦点変換器、その製造装置、および製造方法 |
| EP3982965A4 (de) | 2019-06-12 | 2023-01-25 | Praxis Biotech LLC | Modulatoren des integrierten stressreaktionsweges |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2901336A1 (de) | 1979-01-15 | 1980-07-24 | Boehringer Mannheim Gmbh | Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3209271A1 (de) | 1982-03-13 | 1983-09-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| JPH0655152B2 (ja) * | 1984-08-13 | 1994-07-27 | バイオテクノロジー・オーストラリア・ピーテイーワイ・リミテツド | ミナクチビンの製造方法 |
| US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
-
1998
- 1998-07-23 TR TR2000/00272T patent/TR200000272T2/xx unknown
- 1998-07-23 EP EP98943771A patent/EP1012147B1/de not_active Expired - Lifetime
- 1998-07-23 CA CA002296476A patent/CA2296476A1/en not_active Abandoned
- 1998-07-23 IL IL13419398A patent/IL134193A0/xx unknown
- 1998-07-23 BR BR9811589-8A patent/BR9811589A/pt not_active Application Discontinuation
- 1998-07-23 ID IDW20000173A patent/ID24525A/id unknown
- 1998-07-23 DE DE69832184T patent/DE69832184D1/de not_active Expired - Lifetime
- 1998-07-23 PL PL98338614A patent/PL338614A1/xx not_active Application Discontinuation
- 1998-07-23 HU HU0004221A patent/HUP0004221A2/hu unknown
- 1998-07-23 WO PCT/EP1998/004619 patent/WO1999006387A2/en not_active Application Discontinuation
- 1998-07-23 AU AU91559/98A patent/AU745839B2/en not_active Ceased
- 1998-07-23 KR KR1020007000941A patent/KR100343067B1/ko not_active IP Right Cessation
- 1998-07-23 AT AT98943771T patent/ATE308535T1/de not_active IP Right Cessation
- 1998-07-23 JP JP2000505146A patent/JP3241711B2/ja not_active Expired - Fee Related
- 1998-07-29 AR ARP980103732A patent/AR013374A1/es unknown
- 1998-07-29 UY UY25114A patent/UY25114A1/es not_active Application Discontinuation
- 1998-07-30 PE PE1998000679A patent/PE106099A1/es not_active Application Discontinuation
- 1998-07-31 MA MA25200A patent/MA26528A1/fr unknown
-
1999
- 1999-09-22 US US09/401,403 patent/US6200989B1/en not_active Expired - Fee Related
-
2000
- 2000-01-20 HR HR20000031A patent/HRP20000031A2/hr not_active Application Discontinuation
- 2000-01-25 NO NO20000366A patent/NO20000366D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE308535T1 (de) | 2005-11-15 |
| UY25114A1 (es) | 2001-01-31 |
| US6200989B1 (en) | 2001-03-13 |
| EP1012147A2 (de) | 2000-06-28 |
| TR200000272T2 (tr) | 2000-09-21 |
| HUP0004221A2 (hu) | 2001-04-28 |
| BR9811589A (pt) | 2000-09-19 |
| HRP20000031A2 (en) | 2000-10-31 |
| CA2296476A1 (en) | 1999-02-11 |
| JP2001512113A (ja) | 2001-08-21 |
| JP3241711B2 (ja) | 2001-12-25 |
| EP1012147B1 (de) | 2005-11-02 |
| KR20010022362A (ko) | 2001-03-15 |
| AU9155998A (en) | 1999-02-22 |
| IL134193A0 (en) | 2001-04-30 |
| AR013374A1 (es) | 2000-12-27 |
| DE69832184D1 (de) | 2005-12-08 |
| ID24525A (id) | 2000-07-20 |
| PE106099A1 (es) | 1999-11-11 |
| PL338614A1 (en) | 2000-11-06 |
| WO1999006387A2 (en) | 1999-02-11 |
| WO1999006387A3 (en) | 1999-04-22 |
| NO20000366D0 (no) | 2000-01-25 |
| KR100343067B1 (ko) | 2002-07-03 |
| MA26528A1 (fr) | 2004-12-20 |
| AU745839B2 (en) | 2002-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20000366L (no) | O-substituerte hydroksycoumaranon-derivater som anti-tumor- og antimetastase-midler | |
| NO2018005I1 (no) | tivozanib eller et salt eller solvat derav | |
| HUP0002423A2 (hu) | Fungicid hatású pirimidin-4-on és pirimidin-4-tion-származékok | |
| DK0771794T3 (da) | Oxygenholdige heterocykliske forbindelser | |
| FI832092L (fi) | 1-aryloxi-2,3,4,5-tetrahydro-3-bensazepiner, foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel | |
| DK474485D0 (da) | Dichloranilinderivater | |
| NO20015446D0 (no) | Kinolin-derivater som inhibitorer for MEK-enzymer | |
| NO895232D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive cykloalkanderivater. | |
| ATE39350T1 (de) | Aminophenolderivate. | |
| DK534381A (da) | Fremgangsmaade til fremstilling af 2-oxoazetidinderivater | |
| HUP0302961A2 (hu) | (Aminoalkoxibenzoil) benzofuránok vagy benzotiofének, eljárás ilyen vegyületek előállítására és ilyen vegyületeket tartalmazó készítmények | |
| MY101917A (en) | Biocidal mixture | |
| BR8500851A (pt) | Processo para produzir um derivado de benzoilureia e processo para produzir uma composicao inseticida e/ou ovicida | |
| MY109517A (en) | Carboxylic acid derivatives | |
| ES8404312A1 (es) | Un procedimiento para la preparacion de derivados de etanolamina. | |
| AR246120A1 (es) | Derivados de n'-alquil-n,n'diacilhidracina insecticidamente activos y composicion que los comprende. | |
| AU623500B2 (en) | Carboxylimino benzothiazole derivatives | |
| SE8604349D0 (sv) | Dikloranilinderivat | |
| HUP0101736A2 (hu) | Izoxazolo[3,4-c]kinolin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| WO1991000729A3 (en) | Bis-dioxopiperazines, and their use as protecting agents | |
| HUP0002075A2 (hu) | Fungicid keverékek | |
| NO944577L (no) | Hemming av effekten av amyloidogene proteiner | |
| TW350835B (en) | Process for preparing nitroaniline derivatives | |
| DE3067896D1 (en) | Process for the production of azo compounds | |
| DK0401125T3 (da) | Biphenylderivater, fremgangsmåde til fremstilling af disse samt mellemprodukter derfor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |